Disease Overview：Colorectal Cancer（CRC）
Colorectal cancer—encompassing both colon and rectal malignancies—is a leading cause of cancer-related morbidity and mortality worldwide. It originates from adenomatous polyps or de novo epithelial lesions in the large intestine, with risk factors including age (>50 years), familial syndromes (e.g., Lynch syndrome, familial adenomatous polyposis), inflammatory bowel disease, obesity, smoking, and diets high in processed meats. Early-stage disease is often asymptomatic; later presentations may include hematochezia, change in bowel habits, abdominal pain, unexplained weight loss, or iron-deficiency anemia. Diagnosis relies on colonoscopy with biopsy, supplemented by cross-sectional imaging (CT/MRI) and molecular profiling (e.g., KRAS/NRAS/BRAF, MSI/MMR status) to guide prognosis and therapy selection. Treatment is multidisciplinary: surgical resection remains curative for localized disease; neoadjuvant chemoradiotherapy is standard for locally advanced rectal cancer; adjuvant chemotherapy improves survival in stage III; and targeted biologics (e.g., anti-EGFR or anti-VEGF agents) plus immunotherapy are increasingly used in metastatic settings.
China offers compelling advantages for international patients seeking colorectal cancer care. Its tertiary hospitals—many accredited by JCI or ISO—house oncology centers led by nationally recognized surgeons and medical oncologists with extensive experience in complex resections, robotic-assisted surgery (da Vinci Xi), and organ-preserving strategies. Advanced diagnostics—including next-generation sequencing, PET-MRI fusion imaging, and liquid biopsy—are widely available. Five-year overall survival rates for stage II–III disease exceed 70% in top-tier institutions, supported by robust clinical trial participation and real-world outcome data. Crucially, treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising quality—making comprehensive care, including genetic testing and extended follow-up, highly accessible.
As a dedicated medical tourism agency, we facilitate seamless access to this high-value care: vetting accredited hospitals, coordinating appointments with specialists, clarifying all-inclusive pricing upfront, arranging visas and accommodation, and providing bilingual clinical liaison and post-treatment support—all tailored to individual clinical needs and cultural preferences.
Colorectal Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Colorectal Cancer (Oncology Department)
Non-Surgical / Medical Therapy
*Indicated for Stage II–IV, unresectable disease, adjuvant/neoadjuvant settings, or palliation.*
- •Chemotherapy (FOLFOX/FOLFIRI):
- *Cost (per cycle)*: ¥8,500–¥12,000 → $1,180–$1,670 - Oxaliplatin (generic): ¥3,200 - 5-FU + leucovorin infusion: ¥2,100 - Supportive antiemetics (palonosetron + dexamethasone): ¥480 - Day-care nursing & IV administration: ¥1,900
- •Targeted Therapy (anti-EGFR/VEGF):
- *Cost (per dose)*: - Cetuximab (250 mg/m²): ¥14,200 → $1,975 - Bevacizumab (7.5 mg/kg): ¥5,600 → $780
- •Immunotherapy (PD-1 inhibitors):
- *Cost (per 200 mg dose)*: - Sintilimab: ¥6,800 → $945 - Toripalimab: ¥5,900 → $820
- •Diagnostic/Lab Fees (per cycle):
- CBC, LFTs, creatinine: ¥280 → $39 - RAS/BRAF testing (NGS panel): ¥2,400 → $334
Surgical / Procedural Options
*Indicated for localized (Stage I–III) or oligometastatic (liver/lung) disease.*
- •Laparoscopic Colectomy (Right/Left/Sigmoid):
- *Cost*: ¥32,000–¥45,000 → $4,450–$6,260 - Surgeon/anesthesia fees: ¥14,500 - Laparoscopic instruments & disposables: ¥9,800 - ICU monitoring (1 day avg): ¥3,200
- •Robotic-Assisted Resection:
- *Cost*: ¥58,000–¥72,000 → $8,070–$10,020
- •Preoperative Workup (mandatory):
- Pelvic MRI (rectal cancer): ¥1,800 → $250 - Cardiopulmonary evaluation (ECG, echo, PFTs if >65 yrs): ¥1,350 → $188
Special/Complex Scenarios
- •Liver Metastasectomy (open/robotic): ¥65,000–¥89,000 → $9,040–$12,380
- •Neoadjuvant Chemoradiation (rectal): 25 fractions + capecitabine: ¥24,000 → $3,340
- •Palliative Stent Placement (obstructing tumor): ¥15,500 → $2,155
Quick Selection Guide
- •<60 yrs, Stage III, fit: Laparoscopic colectomy + adjuvant FOLFOX ($4,450–$6,260 + $1,180/cycle × 12)
- •>75 yrs, comorbidities, Stage II: Single-agent capecitabine (¥3,800/cycle → $530) + surveillance
- •MSI-H Stage IV, limited mets: Immunotherapy first-line ($945/dose q3w) — avoids chemo toxicity
- •Budget-constrained (<$5,000 total): Palliative stent + best supportive care ($2,155 + $300/month)
- •Locally advanced rectal: Neoadjuvant chemoradiation → surgery ($3,340 + $4,450+) — improves sphincter preservation
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Colorectal Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Colorectal Cancer treatment with China top medical destinations:
